ArticleEmerging infectious diseases2006
Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
Article in Emerging infectious diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics.PloS one · 2012Pooled it
- The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?Cost effectiveness and resource allocation : C/E · 2023Article
- Maintaining efficient logistics and supply chain management operations during and after coronavirus (COVID-19) pandemic: learning from the past experiences.Environment, development and sustainability · 2021Review
- Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage.F1000Research · 2016Article
- High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.PloS one · 2016Article
- Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.BMC public health · 2013Article
- The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.PloS one · 2013Article
- Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.Journal of the Royal Society, Interface · 2011Article
- Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza.PloS one · 2011Article
- Article
- Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.Emerging infectious diseases · 2010Article
- Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.BMC infectious diseases · 2010Article
- Optimizing tactics for use of the U.S. Antiviral Strategic National Stockpile for Pandemic (H1N1) Influenza, 2009.PLoS currents · 2009Article
- Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.European journal of public health · 2009Article
- Article
- The impact of prophylaxis of healthcare workers on influenza pandemic burden.Journal of the Royal Society, Interface · 2007Article
- Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza.Emerging infectious diseases · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared strategies for stock piling neuraminidase inhibitors to treat and prevent influenza in Singapore. Cost-benefit and cost-effectiveness analyses, with Monte Carlo simulations, were used to determine economic outcomes. A pandemic in a population of 4.2 million would result in an estimated 525-1,775 deaths, 10,700-38,600 hospitalization days, and economic costs of 0.7 dollars to 2.2 billion Singapore dollars. The treatment-only strategy had optimal economic benefits: stock piles of antiviral agents for 40% of the population would save an estimated 418 lives and 414 million dollars, at a cost of 52.6 million dollars per shelf-life cycle of the stock pile. Prophylaxis was economically beneficial in high-risk subpopulations, which account for 78% of deaths, and in pandemics in which the death rate was >0.6%. Prophylaxis for pandemics with a 5% case-fatality rate would save 50,000 lives and 81 billion dollars. These models can help policymakers weigh the options for pandemic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.